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Objective. To report an unusual case of ovarian Leydig cell hyperplasia resulting in virilization in a postmenopausal woman.
Methods. Patient’s medical history and pertinent literature were reviewed. Results. A 64-year-old woman presented with virilization
with worsening hirsutism, deepening of her voice, male musculature, and male pattern alopecia. Her pertinent past medical history
included type 1 diabetes, hyperlipidemia, and hypertension. Her pertinent past surgical history included hysterectomy due to
fibroids. On further work-up, her serum total testosterone was 506 ng/dL (nl range: 2–45) and free testosterone was 40 pg/mL (nl
range: 0.1–6.4). After ruling out adrenal causes, the patient underwent an empiric bilateral oophorectomy that showed Leydig cell
hyperplasia on pathology. Six weeks postoperatively, serum testosterone was undetectable with significant clinical improvement.
Conclusion. Postmenopausal hyperandrogenism can be the result of numerous etiologies ranging from normal physiologic changes
to ovarian or rarely adrenal tumors. Our patient was found to have Leydig cell hyperplasia of her ovaries, a rarely reported cause of
virilization.

1. Introduction
In a postmenopausal woman, evaluation of virilization
includes ruling out a variety of causes before ovarian sampling or empiric oophorectomy. Mild hirsutism and alopecia
in postmenopausal women can be a normal physiological response: with a reduction of ovarian follicles, there
is a diminished estrogen and progesterone secretion, thus
increasing the impact of androgens on sebaceous glands and
hair follicles resulting in transformation of vellus to terminal hair follicles [1]. Apart from the normal physiological
changes leading to hirsutism, there are various conditions
that need to be ruled out and/or treated that result in
virilization in postmenopausal patients. Included in these
are polycystic ovary syndrome (PCOS), congenital adrenal

hyperplasia (CAH), Cushing’s syndrome, benign and malignant androgen-secreting ovarian and adrenal tumors, and
iatrogenic causes [1]. This case report is of a patient with a rare
but relevant cause of postmenopausal hyperandrogenism:
ovarian Leydig cell hyperplasia. This pathology, previously
reported in at least seven cases, results in excess testosterone
secretion and the virilizing symptoms of the patient, a
relationship elucidated by disappearance of symptoms after
bilateral salpingooopherectomy.

2. Case Presentation
A 64-year-old woman presented to the endocrinology office
as a referral for evaluation of increasing hirsutism. She had a
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history of irregular menses and facial hirsutism since menarche, but since menopause at age 50, she noticed worsening
hirsutism, diffuse hair loss, deepening of her voice, increased
muscle mass, and increased libido.
Her past medical history included type 1 diabetes, hyperlipidemia, and hypertension. The patient’s past surgical history was significant for a total abdominal hysterectomy for
fibroids. Her obstetrical history was significant for two live
births, both products of ovulation induction. Her medications at the time of the visit included insulin glargine, insulin
aspart, nifedipine, atorvastatin, and valsartan. Her family
history was significant for a mother with heart disease and
hypertension and a father with stroke and hypertension.
Her social history was significant for two drinks a day and
smoking a half-a-pack per day for thirty years.
On physical exam, her blood pressure was 112/74 mm Hg
and a body mass index of 24.9 kg/m2 . She had male pattern
alopecia with mild male musculature and facial hirsutism
on her chin and upper lip. She was neither cushingoid
nor acromegalic. Her external female genitalia were grossly
normal in appearance and her bimanual and rectovaginal
exam failed to demonstrate any masses.
Pertinent laboratory work-up at a previous office showed
the following: serum total testosterone: 588 ng/dL (nl range:
2–45), 17-hydroxyprogesterone: 129 ng/dL (nl range: <45),
cortisol: 14 mcg/dL (nl range: 4–28.6), ACTH: 5 pg/mL
(nl range: 6–50), LH: 43 mIU/mL (nl: 7.7–58.5), and FSH:
41 mIU/mL (nl range: 25.8–135). A basic metabolic profile
was within normal limits. Her HbA1c was 6.2%. Pelvic
and transvaginal ultrasound showed no ovarian masses. On
transvaginal ultrasound, her left ovary measured 2.8 × 2.3
× 2.9 cm and her right measured 2.3 × 1.7 × 1.6 cm, and
no adnexal masses or free fluid collections were visualized.
Magnetic resonance imaging (MRI) of her abdomen and
pelvis showed normal ovaries with few tiny cysts of no
significance and her adrenals were both slightly enlarged
without any masses. MRI of her pituitary was normal.
Repeat laboratory work at our office showed the following: serum cortisol: 8.6 mcg/dL at baseline and 39.2
mcg/dL after cosyntropin stimulation, ACTH: 12 pg/mL (nl
range: 6–50), LH: 32 mIU/mL (nl range: 7.7–58.5), FSH:
49 (nl range: 25.8–135), DHEAS: 68 mcg/dL (nl range: 45–
430), estradiol: 56 pg/mL (nl range: <5.0–54.7), aldosterone:
8 ng/dL (nl range: 4–31), total testosterone: 506 ng/dL (nl
range: 2–45), free testosterone: 40 pg/mL (nl range: 0.1–6.4),
17-hydroxyprogesterone at baseline: 97 ng/dL (nl < 45)
going up to 539 ng/dL at 60 minutes after cosyntropin, 11deoxycortisol: 30 ng/dL (nl < 32) at baseline going up
to 270 ng/dL after cosyntropin, androstenedione: 2.37 ng/mL
(nl: 0.130–0.820), alpha-fetoprotein: 10.3 ng/mL (nl range:
0.0–7.7), and inhibin: 1.1 pg/mL (nl < 7.9). Her karyotype
analysis came back as 46, XX.
In order to rule out late-onset CAH, we performed a
dexamethasone suppression test where the patient was on
dexamethasone 0.5 mg every 6 hours for 5 days and then
underwent repeat serum testosterone, 11-deoxycortisol, and
17-hydroxyprogesterone. After dexamethasone, the patient’s
total testosterone was 646 ng/dL (nl range: 2–45) and her
free testosterone was 60.1 pg/mL (nl range: 0.1–6.4). With
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nonsuppressible total testosterone, late-onset CAH could be
ruled out as a cause of her hyperandrogenism in conjunction with absence of adrenal tumor on imaging. Therefore,
we proceeded with empiric bilateral salpingooopherectomy
as she deferred selective sampling. However, the high 11deoxycortisol postcosyntropin could indicate a mild coexistent late-onset CAH due to 11-hydroxylase deficiency.
The surgical pathology revealed that both the right and
left ovaries contained multiple nodules and small clusters
of bland showing Leydig cells along with unremarkable
fallopian tubes. There was no significant mitotic activity and
no evidence of a concomitant neoplastic stromal component,
only normal appearing ovarian stroma. None of the nodules
was large enough to distort the size and shape of the ovaries
nor was there evidence of a large dominant nodule from
which one might suspect the other nodules could have arisen.
Immunochemistry for inhibin A was strongly positive in
the Leydig cell nodules and helped to confirm the presence
of smaller clusters of Leydig cells interspersed within the
ovarian stroma (Figure 1). The presence of multiple bilateral
nodules of Leydig cells is most compatible with Leydig cell
hyperplasia rather than neoplasia. Six weeks postoperatively,
serum testosterone was undetectable with significant clinical
improvement.

3. Discussion
The patients’ history of long-standing irregular menses and
worsening hirsutism after menopause along with subsequent
deepening voice, male musculature, and male alopecia,
all accompanied by very high serum testosterone levels,
prompted us to rule out late onset (CAH) and/or a small ovarian arrhenoblastoma. Before undergoing an oophorectomy,
we wanted to make sure her high testosterone was not solely
due to CAH.
Her long-standing history of hirsutism, irregular menses,
recent lab findings other than her very high testosterone, and
the slightly enlarged adrenals on imaging could be explained
by late-onset CAH. An adrenal mass was ruled out as the
etiology because adrenal masses secreting testosterone are big
(above 1 cm) and usually cannot be missed by MRI. High
testosterone levels (>150–200 ng/dL) such as hers can be seen
in simple virilizing or salt losing forms of CAH; however,
these forms of CAH are associated with adrenal insufficiency
and high ACTH, both of which the patient did not have.
Small ovarian arrhenoblastomas are known to be small
enough that imaging will not reveal these tumors leading
to the need for ovarian sampling or bilateral oophorectomy.
Since our patient had already undergone menopause, we recommended an oophorectomy rather than ovarian sampling.
Ovarian sampling is very difficult and invasive and even at
the best centers, sampling can accurately localize the ovarian
tumor only 66% of the time [2].
Histologic examination of the patient’s ovaries revealed
multiple small bilateral nodules and interspersed small clusters of Leydig cells that were immunohistochemically positive
for inhibin A. In this clinical context, Leydig cell hyperplasia
is most likely given the small size of the nodules, a lack of a
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Figure 1: Whole-slide sections of left (a) and right (b) ovaries display multiple eosinophilic nodules of Leydig cells (arrows).
Immunohistochemistry for inhibin A highlights the nodules and identifies additional small clusters of Leydig cells (c, whole-slide section,
right ovary). The nodules are composed of Leydig cells, which are polygonal with abundant granular eosinophilic cytoplasm and large
vesicular nuclei (d, H&E, 400x). The Leydig cells display strong cytoplasmic staining with inhibin A (e, 400x).

dominant nodule, and no evidence of metastatic disease. The
fact that the patient’s serum testosterone returned to normal
following bilateral salpingooopherectomy also supports this
contention since any metastatic tumor deposits would be
expected to maintain an elevated serum testosterone. While
inhibin expression is characteristic of Leydig cells, it is not
specific. Inhibin A expression has been observed in many
normal tissues and tumors; however, in the presence of
the appropriate morphologic changes and clinical context,
it can be an extremely useful adjunct for proper pathologic
diagnosis [3]. Ultimately, ovarian Leydig cell hyperplasia
was the etiology of our patient’s symptoms. Though this
pathology can affect both pre- and postmenopausal women,
in our review of the literature, the cases reported have
been of postmenopausal women. The cases tend to have
similar presentations to our patient with a similar workup and, ultimately, a bilateral salpingooopherectomy as the
final treatment. Taylor et al. reported the first case of ovarian Leydig cell hyperplasia in 2000. The hyperplasia was
characterized by small clusters or individual Leydig cells
interspersed within the ovarian cortex in contrast with the
more nodular growth pattern in our patient. Sequencing

of the patient’s LH receptor gene showed no abnormalities
helping to clarify why the virilizing symptoms subsided after
bilateral salpingooopherectomy [4]. Through a case of Leydig
cell hyperplasia, Hofland et al. found that though DHEAS
and imaging have high specificity in detecting adrenal causes
of hyperandrogenism in postmenopausal patients, these tests
are unable to detect ovarian disease [5]. Ali et al. presented
a similar case of a postmenopausal woman with virilization.
High testosterone was found in both ovarian and adrenal
veins resulting in a unilateral adrenalectomy without resolution of symptoms; then, the patient received a bilateral
oophorectomy leading to significant clinical and laboratory
improvement [6]. Zafrakas et al. reported a case of premenopausal Leydig cell hyperplasia presenting as unilateral,
grossly visible, circumscribed mass versus cases of Leydig
cell hyperplasia in postmenopausal women presenting with
bilateral, diffuse microscopic aggregates. They noted that this
pathology in postmenopausal women was benign, making a
bilateral salpingooopherectomy an appropriate cure [7]. Of
note, Yoon et al. reported a case of Leydig cell hyperplasia
in a 65-year-old patient whose only symptom was lumbago.
Unlike our case, patient’s Leydig cell hyperplasia was found
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within a simple cellular fibroma of her left ovary. The patient
did not have androgenic effects of Leydig cell hyperplasia
making it a nonfunctional proliferation [8]. This shows a
difference in distribution of the Leydig cell hyperplasia and,
thus, a difference in phenotype. Tutzer et al. published a
similar case to ours in which a 79-year-old woman with
hirsutism underwent a full work-up to rule out an adrenal
tumor. Ultimately, surgery cured the patient’s virilizing symptoms and ovarian Leydig cell hyperplasia was found [9]. With
more of these rare cases of bilateral Leydig cell hyperplasia
being reported in a very specific patient population, a new
treatment option arises for those who have ruled out adrenal
and/or ovarian causes.

4. Conclusion
Though at least seven cases have been described of this
pathology, it is important to take note of our patient’s presentation and final diagnosis for future work-ups in similarly
presenting patients. With exclusion of adrenal origin and
other obvious ovarian disease, virilization in postmenopausal
women may be the result of Leydig cell hyperplasia for which
a bilateral salpingooopherectomy or bilateral oophorectomy
is the cure. A hyperandrogenic phenotype has a detrimental
effect on the quality of life in postmenopausal patients
as increased facial hair and loss of scalp hair may cause
emotional and psychological distress [1]. It is important to
work these patients up appropriately and understand the
etiologies leading to hyperandrogenism to help alleviate the
stresses associated with menopause and aging.
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